JP2018509397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509397A5 JP2018509397A5 JP2017543916A JP2017543916A JP2018509397A5 JP 2018509397 A5 JP2018509397 A5 JP 2018509397A5 JP 2017543916 A JP2017543916 A JP 2017543916A JP 2017543916 A JP2017543916 A JP 2017543916A JP 2018509397 A5 JP2018509397 A5 JP 2018509397A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- optionally substituted
- halo
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 109
- 125000005843 halogen group Chemical group 0.000 claims 26
- 125000003282 alkyl amino group Chemical group 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 239000003195 sodium channel blocking agent Substances 0.000 claims 12
- -1 nitro, cyano, hydroxy, amino Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229940125794 sodium channel blocker Drugs 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 230000030136 gastric emptying Effects 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005518 carboxamido group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 230000037406 food intake Effects 0.000 claims 3
- 235000012631 food intake Nutrition 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 230000004308 accommodation Effects 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 239000006215 rectal suppository Substances 0.000 claims 1
- 229940100618 rectal suppository Drugs 0.000 claims 1
- 235000018770 reduced food intake Nutrition 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118268P | 2015-02-19 | 2015-02-19 | |
| US62/118,268 | 2015-02-19 | ||
| PCT/US2016/018715 WO2016134283A1 (en) | 2015-02-19 | 2016-02-19 | Methods and compositions for decreasing gastric emptying |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509397A JP2018509397A (ja) | 2018-04-05 |
| JP2018509397A5 true JP2018509397A5 (enExample) | 2019-05-09 |
| JP6762308B2 JP6762308B2 (ja) | 2020-09-30 |
Family
ID=56689101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543916A Active JP6762308B2 (ja) | 2015-02-19 | 2016-02-19 | 胃排出の減少方法及び組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9763955B2 (enExample) |
| EP (1) | EP3258925B1 (enExample) |
| JP (1) | JP6762308B2 (enExample) |
| KR (1) | KR20170117170A (enExample) |
| CN (1) | CN107613965A (enExample) |
| AU (1) | AU2016219879A1 (enExample) |
| BR (1) | BR112017017619A2 (enExample) |
| CA (1) | CA2977367A1 (enExample) |
| IL (1) | IL253949A0 (enExample) |
| MX (1) | MX2017010682A (enExample) |
| PH (1) | PH12017501393A1 (enExample) |
| WO (1) | WO2016134283A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| WO2012085650A1 (en) | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| PT2753606T (pt) | 2011-09-02 | 2017-10-02 | Purdue Pharma Lp | Pirimidinas como bloqueadoras dos canais de sódio |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| WO2015031036A1 (en) | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CA2934473C (en) | 2013-12-23 | 2019-08-20 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
| EP3097078B1 (en) | 2014-01-24 | 2022-05-25 | Purdue Pharma LP | Pyridines and pyrimidines and use thereof |
| BR112017017619A2 (pt) * | 2015-02-19 | 2018-05-08 | Purdue Pharma Lp | métodos e composições para diminuir esvaziamento gástrico |
| CN106397426A (zh) * | 2016-03-29 | 2017-02-15 | 广东环境保护工程职业学院 | 一种1，3，4-噻二唑类化合物及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017490C1 (ru) * | 1990-01-18 | 1994-08-15 | Назаренко Петр Михайлович | Способ лечения демпин-синдрома после резекции желудка по способу бильрот-1 |
| AU6111796A (en) | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor |
| US20040038970A1 (en) * | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| HK1056164B (en) | 2000-03-24 | 2013-06-21 | Euro-Celtique S.A. | Aryl-substituted pyrazole, triazole and tetrazole, and their uses |
| BR0109706A (pt) | 2000-03-31 | 2003-02-04 | Euro Celtique Sa | Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio |
| CA2453633A1 (en) | 2001-07-16 | 2003-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| DE60328087D1 (de) | 2002-03-13 | 2009-08-06 | Euro Celtique Sa | Aryl substituierte pyrimidine und deren verwendung |
| EP1532119A2 (en) | 2002-07-31 | 2005-05-25 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
| US20040213842A1 (en) * | 2003-01-30 | 2004-10-28 | Dynogen Pharmaceuticals, Inc. | Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| EP1533298A1 (en) * | 2003-11-21 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | 3-aminopyrrolidone derivatives |
| CA2595486A1 (en) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| US20070020194A1 (en) * | 2005-06-08 | 2007-01-25 | Greenway Frank L Iii | Nasally administered appetite suppressant |
| EP1984339A1 (en) | 2006-01-23 | 2008-10-29 | Pfizer Limited | Pyridine derivatives as sodium channel modulators |
| EP2078523A4 (en) * | 2006-10-13 | 2010-02-10 | Ajinomoto Kk | AGENT COMPRISING 4-HYDROXYISOLEUCINE FOR THE SUPPRESSION OF GASTRIC DRAIN |
| MX2009004822A (es) | 2006-11-01 | 2009-10-19 | Purdue Pharma Lp | Compuestos de fenilpropionamida y usos de los mismos. |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009012241A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2011158108A2 (en) | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Aryl substituted indoles and the use thereof |
| WO2012004664A2 (en) | 2010-07-07 | 2012-01-12 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| AU2011311238A1 (en) | 2010-10-05 | 2013-04-04 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| WO2012085650A1 (en) | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| PT2753606T (pt) | 2011-09-02 | 2017-10-02 | Purdue Pharma Lp | Pirimidinas como bloqueadoras dos canais de sódio |
| EA023375B1 (ru) | 2011-10-26 | 2016-05-31 | Пфайзер Лимитед | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов |
| AU2012321111A1 (en) | 2011-10-31 | 2013-05-16 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
| WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| JP5938219B2 (ja) * | 2012-01-23 | 2016-06-22 | 株式会社明治 | 胃排出遅延のための食品用の剤または医療用の剤 |
| US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
| US9718865B2 (en) | 2012-07-27 | 2017-08-01 | Purdue Pharma L.P. | Sodium channel blocking peptides and the use thereof |
| AU2014224310B2 (en) * | 2013-03-04 | 2017-02-09 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
| AU2014235063B2 (en) | 2013-03-15 | 2017-05-04 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| BR112017017619A2 (pt) * | 2015-02-19 | 2018-05-08 | Purdue Pharma Lp | métodos e composições para diminuir esvaziamento gástrico |
-
2016
- 2016-02-19 BR BR112017017619A patent/BR112017017619A2/pt not_active Application Discontinuation
- 2016-02-19 AU AU2016219879A patent/AU2016219879A1/en not_active Abandoned
- 2016-02-19 MX MX2017010682A patent/MX2017010682A/es unknown
- 2016-02-19 EP EP16753165.6A patent/EP3258925B1/en active Active
- 2016-02-19 CA CA2977367A patent/CA2977367A1/en not_active Abandoned
- 2016-02-19 US US15/048,530 patent/US9763955B2/en active Active
- 2016-02-19 WO PCT/US2016/018715 patent/WO2016134283A1/en not_active Ceased
- 2016-02-19 JP JP2017543916A patent/JP6762308B2/ja active Active
- 2016-02-19 CN CN201680021578.2A patent/CN107613965A/zh active Pending
- 2016-02-19 KR KR1020177025621A patent/KR20170117170A/ko not_active Withdrawn
-
2017
- 2017-08-03 PH PH12017501393A patent/PH12017501393A1/en unknown
- 2017-08-10 IL IL253949A patent/IL253949A0/en unknown
- 2017-08-18 US US15/680,737 patent/US10143696B2/en active Active